← Leaderboards
David Holt
Case Western Reserve University
$828,670
Attributed
$2,486,011
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $645.9K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,486,011 · 1
By mechanism
R01$2,486,011 · 1
Top collaborators
- James Peter Basilion4 shared
- Xinning Wang4 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Nancy L Oleinick$4,281,905
- Peter A. Zimmerman$15,255,586
- James Peter Basilion$13,402,848
- Duska M Separovic$2,115,239
- John S Witte$28,734,737
Others in their field
Other Emerging Leaders on “Affinity”
- Bala Raja · Luminostics, Inc.$28,624,460
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$25,726,378
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Timothy M Willson · University Of Cape Town$13,865,323
Research focus
AffinityAdverse EventAnimal ModelAnimalsAntibodiesAndrogensAntigensAntigen TargetingAntineoplastic AgentsBindingBiochemicalBiological MarkersAntibody-Drug ConjugatesCancer BiomarkersCancer CellCancer EtiologyCancer HeterogeneityCancer TherapyCanis FamiliarisCarcinomaCell DeathCell KillingCessation Of LifeChemoresistance
Grant awards (4)
Highly selective targeted theranostics for prostate cancers$634,753
R01 · FY2024 · CA
Highly selective targeted theranostics for prostate cancers$641,402
R01 · FY2023 · CA
Highly selective targeted theranostics for prostate cancers$645,854
R01 · FY2022 · CA
Highly selective targeted theranostics for prostate cancers$564,002
R01 · FY2021 · CA